HIV Infections Clinical Trial
Official title:
Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175
| NCT number | NCT00001068 |
| Other study ID # | ACTG 303 |
| Secondary ID | 11278 |
| Status | Completed |
| Phase | Phase 2 |
| First received | |
| Last updated | |
| Est. completion date | October 1998 |
| Verified date | October 2021 |
| Source | National Institute of Allergy and Infectious Diseases (NIAID) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
| Status | Completed |
| Enrollment | 210 |
| Est. completion date | October 1998 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 12 Years and older |
| Eligibility | Inclusion Criteria Patients must have: - Prior participation on protocol ACTG 175. PER AMENDMENT 8/27/96: - Patients must be on study/on treatment at the time the protocol study treatment is extended. |
| Country | Name | City | State |
|---|---|---|---|
| Puerto Rico | Puerto Rico-AIDS CRS | San Juan | |
| Tanzania | Mbeya Med. Research Program, Mbeya Referral Hosp. CRS | Mbeya | |
| United States | Emory Univ. Hemophilia Program Office | Atlanta | Georgia |
| United States | University of Colorado Hospital CRS | Aurora | Colorado |
| United States | Johns Hopkins Adult AIDS CRS | Baltimore | Maryland |
| United States | Alabama Therapeutics CRS | Birmingham | Alabama |
| United States | Beth Israel Deaconess - East Campus A0102 CRS | Boston | Massachusetts |
| United States | Beth Israel Deaconess Med. Ctr., ACTG CRS | Boston | Massachusetts |
| United States | Bmc Actg Crs | Boston | Massachusetts |
| United States | Massachusetts General Hospital ACTG CRS | Boston | Massachusetts |
| United States | SUNY - Buffalo, Erie County Medical Ctr. | Buffalo | New York |
| United States | Unc Aids Crs | Chapel Hill | North Carolina |
| United States | Carolinas HealthCare System, Carolinas Med. Ctr. | Charlotte | North Carolina |
| United States | Cook County Hosp. CORE Ctr. | Chicago | Illinois |
| United States | Northwestern University CRS | Chicago | Illinois |
| United States | Rush Univ. Med. Ctr. ACTG CRS | Chicago | Illinois |
| United States | Univ. of Cincinnati CRS | Cincinnati | Ohio |
| United States | Case CRS | Cleveland | Ohio |
| United States | The Ohio State Univ. AIDS CRS | Columbus | Ohio |
| United States | Regional Center for Infectious Disease, Wendover Medical Center CRS | Greensboro | North Carolina |
| United States | Indiana Univ. School of Medicine, Infectious Disease Research Clinic | Indianapolis | Indiana |
| United States | UCLA CARE Center CRS | Los Angeles | California |
| United States | USC CRS | Los Angeles | California |
| United States | Univ. of Miami AIDS CRS | Miami | Florida |
| United States | University of Minnesota, ACTU | Minneapolis | Minnesota |
| United States | Tulane Hemophilia Treatment Ctr. | New Orleans | Louisiana |
| United States | Beth Israel Med. Ctr. (Mt. Sinai) | New York | New York |
| United States | Cornell University A2201 | New York | New York |
| United States | NY Univ. HIV/AIDS CRS | New York | New York |
| United States | Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr. | Omaha | Nebraska |
| United States | Stanford CRS | Palo Alto | California |
| United States | Hosp. of the Univ. of Pennsylvania CRS | Philadelphia | Pennsylvania |
| United States | Univ. of Rochester ACTG CRS | Rochester | New York |
| United States | St. Louis ConnectCare, Infectious Diseases Clinic | Saint Louis | Missouri |
| United States | Washington U CRS | Saint Louis | Missouri |
| United States | Ucsd, Avrc Crs | San Diego | California |
| United States | Ucsf Aids Crs | San Francisco | California |
| United States | Santa Clara Valley Med. Ctr. | San Jose | California |
| United States | University of Washington AIDS CRS | Seattle | Washington |
| United States | San Mateo County AIDS Program | Stanford | California |
| United States | Harbor-UCLA Med. Ctr. CRS | Torrance | California |
| Lead Sponsor | Collaborator |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) |
United States, Puerto Rico, Tanzania,
Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM; ACTG 303 Study Team. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1337-44. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |